Sepoy-logo
No Result
View All Result
Sunday, December 10, 2023
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

New Weight-Loss Drug Looks Good in Trial

Nicholas by Nicholas
June 8, 2022
in Health
0

READ ALSO

EULAR publishes updated recommendations for SLE management

Women over 50 can safely reduce mammogram frequency after breast cancer surgery


Latest Diet & Weight Management News

By Denise Mann HealthDay Reporter

A newly approved drug for type 2 diabetes may be a game-changer for treating obesity, too.

Given as a shot once a week, tirzepatide works on two naturally occurring hormones that help tell the brain that you are full. It may be as effective as weight-loss surgery.

“About nine of 10 people in the study lost weight, and the average weight loss for the highest dose was 22.5%, which is something we have never seen before,” said study co-author Dr. Ania Jastreboff. She is an associate professor at Yale University School of Medicine and co-director of the Yale Center for Weight Management, in New Haven, Conn.

“These results are an important step forward in potentially expanding effective therapeutic options for people with obesity,” Jastreboff said.

The new trial focused on people who are obese but didn’t have diabetes. It found they lost even more weight than what was seen in the diabetes studies that led to the drug’s approval for this indication in May.

Drug maker Eli Lilly sponsored the new study.

For the 72-week study, more than 2,500 overweight or obese adults received either 5, 10 or 15 mg of the new drug or placebo each week. The average weight reduction for the highest dose was about 52 pounds, the study showed. People who took the 10 mg dose lost about 49 pounds, on average, and those in the 5 mg group shed about 35 pounds. By contrast, people given a placebo injection lost slightly more than 5 pounds. Study volunteers were also counseled on healthy eating and exercise.

Nearly everyone on the drug saw an improvement in blood sugar, blood pressure and cholesterol levels, the study found.

The most common side effects were nausea, diarrhea and constipation, and they were generally mild to moderate, Jastreboff said.

Study participants kept the weight off for the full 72-week study period. “Obesity is a chronic treatable disease. We should treat obesity as we treat any chronic disease — with effective and safe approaches which target underlying disease mechanisms, and these results underscore that tirzepatide may be doing just that,” she said.

People may need to stay on the medication indefinitely. “If we think of obesity as a chronic disease, then why would we treat a chronic disease for only 72 weeks?” Jastreboff said.

Individuals who developed prediabetes were not included in the new analysis. They will be followed for two years to see how they fare on the new drug. People with prediabetes have higher-than-normal blood sugar levels, but do not have full-blown diabetes yet.

The study was presented Saturday at the annual meeting of the American Diabetes Association, in New Orleans, and simultaneously published in the June 4 issue of the New England Journal of Medicine.

“This study is a big deal,” said Dr. Scott Kahan, director of the National Center for Weight and Wellness in Washington, D.C. “Tirzepatide is the first medication of a new class of medications that will likely become the preeminent medications for both diabetes and obesity treatment,” said Kahan, who has no ties to the study.

“We currently have quite good medications available for weight management — but the magnitude of weight loss far exceeds all other medications,” he said. Moreover, it “approaches the amount of weight loss with the most common bariatric surgical procedures,” he added.




SLIDESHOW


How to Lose Weight Without Dieting: 24 Fast Facts
See Slideshow

Also, nearly everyone treated with the medication lost at least a modest amount of weight, if not much more, Kahan said.

So how does this new shot compare to other prescription weight-loss drugs? Kahan said that it looks like a winner.

An obesity treatment approved last year called semaglutide (Wegovy) produces about 15% weight loss. It targets human glucagon-like peptide-1 (GLP-1), but the new drug targets GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which may be why it appears even more effective.

“Other medications approved in the last decade lead to an average of between 10% and nearly 15% weight loss. The most frequently prescribed weight loss drug in the United States — phentermine (Adipex-P, Lomaira), which was approved by the U.S. Food and Drug Administration in 1959 — typically leads to just 5% to 7% weight loss,” Kahan said.

If and when this drug is approved for weight loss, cost will be a consideration, he said.

For diabetes, it is estimated to cost around $800 per month, but it will likely be covered by insurance. “Weight medications are traditionally different because they tend not to be covered by insurance so people have to pay out of pocket,” Kahan noted. It’s too early to predict the cost of tirzepatide for obesity.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about medications that treat obesity.

SOURCES: Ania Jastreboff, MD, PhD, associate professor, Yale University School of Medicine, and director, weight management and obesity prevention, Yale Stress Center, and co-director, Yale Center for Weight Management, New Haven, Conn.; Scott Kahan, MD, MPH, director, National Center for Weight and Wellness, Washington, D.C.; American Diabetes Association meeting, New Orleans, June 3–7, 2022; New England Journal of Medicine, June 4, 2022

MedicalNews

Copyright © 2021 HealthDay. All rights reserved.

Tags: New Weight Loss Drug Looks Good in Trial

Related Posts

EULAR publishes updated recommendations for SLE management
Health

EULAR publishes updated recommendations for SLE management

December 9, 2023
Women over 50 can safely reduce mammogram frequency after breast cancer surgery
Health

Women over 50 can safely reduce mammogram frequency after breast cancer surgery

December 9, 2023
Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds
Health

Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

December 9, 2023
MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers
Health

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

December 9, 2023
New insights into how anti-obesity drugs could help prevent kidney disease
Health

New insights into how anti-obesity drugs could help prevent kidney disease

December 9, 2023
Brain activity measured in living tissue using diamond sensors
Health

Brain activity measured in living tissue using diamond sensors

December 9, 2023
Next Post

Aaron Kwok, Francis Ng Reunite for ‘Insider’ as Hong Kong Film Production Perks Up

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

POPULAR NEWS

Roblox Is Unbreakable Trello Is this safe?

Roblox Is Unbreakable Trello Is this safe?

November 4, 2022
Discord Registered Games  Discord Registered Gaming You need to join the Club

Discord Registered Games Discord Registered Gaming You need to join the Club

November 4, 2022
How To Chose the Right Data Analytics Program

How To Chose the Right Data Analytics Program

November 4, 2022
Heavy explosion on market square in Halle – three injured

Heavy explosion on market square in Halle – three injured

November 4, 2022

Shivon Zilis Wiki, Height, Age, Boyfriend, Husband, Family, Biography & More

July 11, 2022

EDITOR'S PICK

Men More Prone to Cancer Than Women, But Why?

August 12, 2022
Checkout Free things do in Mysore for a budget trip

Checkout Free things do in Mysore for a budget trip

March 4, 2023
How Does Self-Inflating Air Mattress Work?

How Does Self-Inflating Air Mattress Work?

November 19, 2022

Fighting at the Zaporizhia nuclear power plant shortly before the IAEA visit

September 1, 2022

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: [email protected]

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Illuvium (ILV), un écosystème de jeux Play to Earn aux gameplay variés
  • Nach Anhörung zu Antisemitismus: Uni-Präsidentin in den USA tritt zurück
  • Parteitag: SPD sieht frühere Russlandpolitik als Fehler

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net

x